Bronchial Artery Embolization and Bronchoscopy in The Management of Hemoptysis in Cavitary Tuberculosis Lung Lesions
Efficacy of Bronchial Artery Embolization and Bronchoscopy in The Management of Hemoptysis in Cavitary Tuberculosis Lung Lesions
This study aimed to evaluate the efficacy and safety of combining Bronchial artery embolization with bronchoscopy in the management of hemoptysis in patients with cavitary pulmonary tuberculosis.
研究概览
地位
详细说明
The lungs have a dual arterial supply composed of the pulmonary and bronchial arterial systems. The pulmonary arteries account for 99% of the arterial supply and are responsible for gaseous exchange.
Combining bronchoscopy with Bronchial artery embolization may improve treatment outcomes and reduce recurrence rates. Despite the increasing use of Bronchial artery embolization, limited studies have evaluated the combined role of bronchoscopy and Bronchial artery embolization specifically in patients with cavitary pulmonary tuberculosis.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Mohamad B Abd-Elhafiz, MBBCH
- 电话号码:00201140466319
- 邮箱:mohamedbahget1990@gmail.com
学习地点
-
-
-
Asyut、埃及、71511
- 招聘中
- Al-Azhar University (Assiut)
-
接触:
- Mohamad B Abd-Elhafiz, MBBCH
- 电话号码:00201140466319
- 邮箱:mohamedbahget1990@gmail.com
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Age > 18 years.
- Confirmed pulmonary tuberculosis.
- Presence of cavitary lung lesions on computed tomography (CT) chest.
- Moderate or massive hemoptysis requiring intervention.
- Written informed consent.
Exclusion Criteria:
- Coagulopathy not corrected before intervention .
- Severe cardiac instability.
- Pregnancy.
- Pulmonary malignancy.
- Refusal to participate.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器:Group A
Patients will undergo bronchial artery embolization alone. |
Patients will undergo bronchial artery embolization alone. |
|
实验性的:Group B
Patients will undergo bronchial artery embolization combined with bronchoscopy. |
Patients will undergo bronchial artery embolization combined with bronchoscopy. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Proportion of Participants Achieving Successful Control of Hemoptysis
大体时间:24 hours after completion of the assigned intervention
|
Percentage of participants achieving complete cessation of hemoptysis without requiring an additional intervention to control bleeding will be recorded. |
24 hours after completion of the assigned intervention
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Proportion of Participants With Recurrent Hemoptysis
大体时间:24 hours after completion of the assigned intervention
|
Percentage of participants experiencing a new episode of hemoptysis after initial successful bleeding control will be recorded. |
24 hours after completion of the assigned intervention
|
|
All-Cause Mortality
大体时间:24 hours after completion of the assigned intervention
|
Percentage of participants who die from any cause during the specified follow-up period will be recorded. |
24 hours after completion of the assigned intervention
|
|
Need for repeat embolization
大体时间:24 hours after completion of the assigned intervention
|
Percentage of participants requiring an additional bronchial artery embolization procedure because of persistent or recurrent hemoptysis will be recorded. |
24 hours after completion of the assigned intervention
|
|
Incidence of procedure-related complications
大体时间:24 hours after completion of the assigned intervention
|
Incidence of procedure-related complications will be recorded. |
24 hours after completion of the assigned intervention
|
|
Length of hospital stay
大体时间:Till discharge from the hospital (Up to two weeks)
|
Length of hospital stay will be recorded from the admission till discharge from the hospital |
Till discharge from the hospital (Up to two weeks)
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- AZFM-IRB/M-1000/2026/09/012
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
IPD 共享时间框架
After the end of study for one year.
IPD 共享访问标准
The data will be available upon a reasonable request from the corresponding author.
IPD 共享支持信息类型
- 研究方案
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.